Ranbaxy Laboratories to open its second plant in Malaysia
The new plant will increase the capacity of the Ranbaxy by two million doses per annum in Malaysia.
New Delhi, September 13, 2012: The drug maker Ranbaxy Laboratories has received the required approval from the Malaysian authorities to set up its second manufacturing unit in the country. It is expected that the new unit will attract an investment of Rs 220 crore (US$ 40 million).
The company said in a statement that Ranbaxy Malaysia Sdn Bhd, a subsidiary of Ranbaxy Laboratories has received the approval to set up the Greenfield manufacturing plant in Malaysia as an EPP (Entry Project Point). The company also mentioned that the project will provide employment to over 200 people.
It may be noted here that the new facility will manufacture dosage forms, including tablets and capsules focusing on segments like cardiovascular, anti-diabetic, anti-infective and gastrointestinal.
As the new plant will become operational, it will increase the capacity of the company from one billion doses per annum to three billion doses per annum. The company opened its first plant in Malaysia back in 1987 and it currently employs over 300 people in the country.
Apart from serving the local market, the plant will also export to destinations like ASEAN, Middle East, Europe, Sri Lanka, China and other select countries.